Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05667142 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05667142 · ClinicalTrials.gov record · last posted 2026-08-10

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Name: A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures — clinical trial record (NCT05667142)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: X-ACKT

StatusRecruiting

PhasePhase 3

SponsorXenon Pharmaceuticals Inc.

Started2023-02-14

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).

Amendment record 28 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 28 times since 2022-12-27; most recent amendment 2026-07-07. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-02-27

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT05667142
Lead Sponsor	Xenon Pharmaceuticals Inc. Collaborators: Worldwide Clinical Trials
Conditions	Primary Generalized Tonic-Clonic Seizures
Enrollment	160 participants
Start Date	2023-02-14
Primary Completion	2027-04 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-10